Clinical Trial Update: Experience of 177Lu-PSMA-617-administration on Port Reservoir (TIVAP)

View source ↗

Summary

This clinical trial update describes experiences administering Lutetium-177-PSMA-617 via a port reservoir (TIVAP). The study is currently recruiting at a French…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Central Hospital, Nancy, France | Conditions: Administration of Therapy | Status: RECRUITING